UB Paderborn / Katalog / Suche / in CDI

Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States

Journal of health economics and outcomes research (Online), 2023, Vol.10 (2), p.104-110

2023

Link zum Volltext

Verfügbarkeit prüfen

Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States

Journal of health economics and outcomes research (Online), 2023-10, Vol.10 (2), p.82-90

2023

Link zum Volltext

Verfügbarkeit prüfen

Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L

Journal of patient-reported outcomes, 2020-03, Vol.4 (1), p.22-22, Article 22

2020

Link zum Volltext

Verfügbarkeit prüfen

The comparative clinical effectiveness of dostarlimab versus doxorubicin in the treatment of advanced/recurrent endometrial cancer (216)

Gynecologic oncology, 2022-08, Vol.166, p.S120

2022

Link zum Volltext

Verfügbarkeit prüfen

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer

The oncologist (Dayton, Ohio), 2022-12, Vol.27 (12), p.1058-1066

2022

Link zum Volltext

Verfügbarkeit prüfen

Correction to: An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer

The oncologist (Dayton, Ohio), 2023-05, Vol.28 (5), p.e313-e313

2023

Link zum Volltext

Verfügbarkeit prüfen

MO23-2 Characteristics, treatment patterns, and healthcare costs of advanced/metastatic biliary tract cancer patients in Japan

Annals of oncology, 2022-07, Vol.33, p.S496

2022

Link zum Volltext

Verfügbarkeit prüfen

Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States

Journal of health economics and outcomes research (Online), 2023, p.104-110

2023

Link zum Volltext

Verfügbarkeit prüfen

Association Between Intermediate End Points, Progression-Free Survival, and Overall Survival in First-Line Advanced or Recurrent Endometrial Cancer

Clinical therapeutics, 2023-10, Vol.45 (10), p.983-990

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Ibrutinib-Rituximab versus Real-World (RW) Treatments for Patients with Waldenström's Macroglobulinemia (WM): Adjusted Comparison of iNNOVATE and the Lyon-Sud RW Database

Blood, 2018-11, Vol.132 (Supplement 1), p.1604-1604

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review

Critical reviews in oncology/hematology, 2021-02, Vol.158, p.103212-103212, Article 103212

2021

Link zum Volltext

Verfügbarkeit prüfen

A note on the relationship between age and health-related quality of life assessment

Quality of life research, 2019-05, Vol.28 (5), p.1201-1205

2019

Link zum Volltext

Verfügbarkeit prüfen

T-CREST: Time-predictable multi-core architecture for embedded systems

Journal of systems architecture, 2015-10, Vol.61 (9), p.449-471

2015

Link zum Volltext

Verfügbarkeit prüfen

A Globally Arbitrated Memory Tree for Mixed-Time-Criticality Systems

IEEE transactions on computers, 2017-02, Vol.66 (2), p.212-225

2017

Link zum Volltext
IEEE_Xplore

Single-Agent Ibrutinib vs Real-World (RW) Treatments for Patients with Chronic Lymphocytic Leukemia (CLL) and del11q: Adjusted Comparison of RESONATE-2TM and RESONATETM with RW Databases

Blood, 2018-11, Vol.132 (Supplement 1), p.4427-4427

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States

Journal of health economics and outcomes research (Online), 2023-10, p.82-90

2023

Link zum Volltext

Verfügbarkeit prüfen

Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety

Future oncology (London, England), 2022-06, Vol.18 (18), p.2321-2338

2022

Link zum Volltext

Verfügbarkeit prüfen

Systematic Literature Review of the Clinical Efficacy and Safety of Treatments in the Relapsed/Refractory Setting for Patients with Follicular Lymphoma or Marginal Zone Lymphoma

Blood, 2017-12, Vol.130, p.2783-2783

2017

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5504-5504

2023

Link zum Volltext

Verfügbarkeit prüfen

Systematic Reviews of the Clinical Efficacy and Safety of First-Line Treatments for Patients with Mantle Cell Lymphoma

Blood, 2018-11, Vol.132 (Supplement 1), p.5868-5868

2018

Link zum Volltext

Verfügbarkeit prüfen

Systematic Literature Review of the Cost-Effectiveness of Treatments, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma

Blood, 2018-11, Vol.132 (Supplement 1), p.5848-5848

2018

Link zum Volltext

Verfügbarkeit prüfen

Burden of illness of follicular lymphoma and marginal zone lymphoma

Annals of hematology, 2019-01, Vol.98 (1), p.175-183

2019

Link zum Volltext

Verfügbarkeit prüfen

Systematic literature review of the global burden of illness of mantle cell lymphoma

Current medical research and opinion, 2020-05, Vol.36 (5), p.843-852

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparative Effectiveness of Single-Agent Ibrutinib in the Ray Trial Versus Real-World Treatment in the Lyon-Sud Database in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Blood, 2017-12, Vol.130, p.2770-2770

2017

Link zum Volltext

Verfügbarkeit prüfen

Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia

Annals of hematology, 2019-12, Vol.98 (12), p.2749-2760

2019

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States

Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States

Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L

The comparative clinical effectiveness of dostarlimab versus doxorubicin in the treatment of advanced/recurrent endometrial cancer (216)

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer

Correction to: An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer

MO23-2 Characteristics, treatment patterns, and healthcare costs of advanced/metastatic biliary tract cancer patients in Japan

Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States

Association Between Intermediate End Points, Progression-Free Survival, and Overall Survival in First-Line Advanced or Recurrent Endometrial Cancer

Efficacy of Ibrutinib-Rituximab versus Real-World (RW) Treatments for Patients with Waldenström's Macroglobulinemia (WM): Adjusted Comparison of iNNOVATE and the Lyon-Sud RW Database

Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review

A note on the relationship between age and health-related quality of life assessment

T-CREST: Time-predictable multi-core architecture for embedded systems

A Globally Arbitrated Memory Tree for Mixed-Time-Criticality Systems

Single-Agent Ibrutinib vs Real-World (RW) Treatments for Patients with Chronic Lymphocytic Leukemia (CLL) and del11q: Adjusted Comparison of RESONATE-2TM and RESONATETM with RW Databases

Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States

Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety

Systematic Literature Review of the Clinical Efficacy and Safety of Treatments in the Relapsed/Refractory Setting for Patients with Follicular Lymphoma or Marginal Zone Lymphoma

Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial

Systematic Reviews of the Clinical Efficacy and Safety of First-Line Treatments for Patients with Mantle Cell Lymphoma

Systematic Literature Review of the Cost-Effectiveness of Treatments, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma

Burden of illness of follicular lymphoma and marginal zone lymphoma

Systematic literature review of the global burden of illness of mantle cell lymphoma

Comparative Effectiveness of Single-Agent Ibrutinib in the Ray Trial Versus Real-World Treatment in the Lyon-Sud Database in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia

Suchergebnisse filtern